Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer

Bone Marrow Transplantation

Volumn 37, Issue 3, 2006, Pages 311-315

  Bregni, Macro ^a   Fleischhauer, K ^a   Bernardi, M ^a   Pescarollo, A ^a   Guggiari, E ^a   Lunghi, F ^a   Deola, S ^a   Scaramuzza, S ^a   Re, F ^a   Setola, E ^a   Monari, M ^a,b   Mazzi, B ^a   Servida, P ^a   Corradini, P ^b   Peccatori, J ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Allogeneic bone marrow transplantation; Breast cancer; Mammaglobin

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MAMMAGLOBIN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; HUMAN TISSUE; LYMPHOCYTE TRANSFUSION; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIBLING; TREATMENT RESPONSE;

ADULT; BONE MARROW; BONE MARROW NEOPLASMS; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRAFT SURVIVAL; GRAFT VS TUMOR EFFECT; HUMANS; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASM PROTEINS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TUMOR MARKERS, BIOLOGICAL; UTEROGLOBIN; VIDARABINE;

EID: 33645320590     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705248     Document Type: Article

References (32)

1. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
2. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
3. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
4. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
5. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
6. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
7. Bregni M, Bernardi M, Ciceri F, Peccatori J. Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol 2004; 26: 95-108.
8. Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002; 51: 539-546.
9. Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, Sinnett HD et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: Comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000; 18: 1432-1439.
10. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-1658.
11. Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up. Breast Cancer Res Treat 1998; 49: 27-33.
12. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study. Lancet 1999; 354: 197-202.
13. Vannucchi AM, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R et al. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. Br J Haematol 1998; 103: 610-617.
14. Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001; 19: 1468-1475.
15. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 3669-3674.
16. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J et al. Simultaneous immunocytochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 960-971.
17. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich RM et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533.
18. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
19. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
20. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-1424.
21. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000; 18: 80-86.
22. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999; 5: 3999-4004.
23. Braun S, Vogl FD, Janni W, Marth C, Schlimok G, Pantel K. Evaluation of bone marrow in breast cancer patients: Prediction of clinical outcome and response to therapy. Breast 2003; 12: 397-404.
24. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK et al. Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998; 185: 427-434.
25. Corradini P, Voena C, Astolfi M, Delloro S, Pilotti S, Arrigoni G et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann Oncol 2001; 12: 1693-1698.
26. Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999; 17: 870-879.
27. Suchy B, Austrup F, Driesel G, Eder C, Kusiak I, Uciechowski P et al. Detection of mammaglobin expressing cells in blood of breast cancer patients. Cancer Lett 2000; 158: 171-178.
28. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 1996; 41: 1-13.
29. Pecora AL, Lazarus HM, Jennis AA, Preti RA, Goldberg SL, Rowley SD et al. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: Predictors and clinical relevance. Biol Blood Marrow Transplant 2002; 8: 536-543.
30. Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A et al. Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer. Clin Cancer Res 2004; 10: 6039-6046.
31. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O et al. Standardization of the immunocytochemical detection of cancer cells in bone marrow and blood. I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999; 1: 377-388.
32. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-320.